Business Description
Kuros Biosciences Ltd
ISIN : CH0325814116
Total Employee Number:
178Description
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 13.68 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.16 | |||||
Interest Coverage | 24.38 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 10.27 | |||||
Beneish M-Score | -1.68 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 88 | |||||
3-Year FCF Growth Rate | 32.6 | |||||
3-Year Book Growth Rate | 4.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 152.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 34.48 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 2.55 | |||||
9-Day RSI | 8.6 | |||||
14-Day RSI | 14.23 | |||||
3-1 Month Momentum % | -12.85 | |||||
6-1 Month Momentum % | -35.45 | |||||
12-1 Month Momentum % | -29.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.96 | |||||
Quick Ratio | 1.45 | |||||
Cash Ratio | 0.45 | |||||
Days Inventory | 311.6 | |||||
Days Sales Outstanding | 51.89 | |||||
Days Payable | 196.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.3 | |||||
Shareholder Yield % | -0.22 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 88.6 | |||||
Operating Margin % | 6.13 | |||||
Net Margin % | 1.75 | |||||
EBITDA Margin % | 5.99 | |||||
FCF Margin % | -1.95 | |||||
OCF Margin % | -0.28 | |||||
ROE % | 3.64 | |||||
ROA % | 2.43 | |||||
ROIC % | 5.62 | |||||
3-Year ROIIC % | 43.62 | |||||
ROC (Joel Greenblatt) % | 37.77 | |||||
ROCE % | 7.09 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 255.28 | |||||
Forward PE Ratio | 47.33 | |||||
PE Ratio without NRI | 298.95 | |||||
PS Ratio | 4.61 | |||||
PB Ratio | 7.47 | |||||
Price-to-Tangible-Book | 14.56 | |||||
EV-to-EBIT | 131.3 | |||||
EV-to-EBITDA | 80.42 | |||||
EV-to-Revenue | 4.79 | |||||
EV-to-Forward-Revenue | 13.38 | |||||
EV-to-FCF | -245.14 | |||||
Price-to-GF-Value | 0.42 | |||||
Price-to-Median-PS-Value | 0.35 | |||||
Price-to-Graham-Number | 13.13 | |||||
| Price-to-Net-Current-Asset-Value | 19.09 | |||||
Earnings Yield (Greenblatt) % | 0.76 | |||||
FCF Yield % | -0.4 |
Kuros Biosciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kuros Biosciences Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| 0.01:1 Stock Split | 2016-06-23 | 28.71 (+0.00%) |
Show
Entries
Guru Commentaries on OTCPK:CSBTF
No articles.
Press Release
Articles on Kuros Biosciences Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers